Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Capsugel Expands Micro-Dosing Services | Contract Pharma

What are you searching for?

Sign in
Breaking News

Capsugel Expands Micro-Dosing Services

Combines proprietary Xcelodose technology with best practices established at Xcelience

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Capsugel has unveiled plans to expand its micro-dosing services offering for early-phase feasibility work. Capsugel’s offering combines its proprietary Xcelodose Precision Powder Micro-Dosing Systems with powder-in-capsule/powder-in-bottle (PIC/PIB) technology developed at Xcelience, which Capsugel acquired in January. By replicating the methods developed at Xcelience’s operations in Tampa, FL, at Capsugel’s product development and manufacturing facility in Ploërmel, France, the company can now offer its micro-dosing capabilities in both North America and Europe.

“Today’s announcement builds on Capsugel’s track record of engineering excellence while demonstrating our ability to integrate new capabilities for the benefit of our customers,” said Amit Patel, president, Capsugel Dosage Form Solutions. “By leveraging best practices pioneered by Xcelience, an array of Xcelodose technologies and our high-containment capability, we have further strengthened our speed-to-product toolkit, enabling us to deliver even greater value to our customers.”

Capsugel’s micro-dosing services are designed to help minimize the cost and time requirements associated with early feasibility work. The company says Xcelodose technology facilitates rapid, automated and consistent PIC/PIB programs that remove the need for excipient compatibility and stability studies for Phase I evaluations, allow for the rapid screening of API candidates, and reduce early-stage product development time by as much as 45 percent. With five Xcelodose units in the U.S. and two in Europe, including Capsugel’s recently added isolator capability in Ploërmel, the company can handle highly potent active pharmaceutical ingredients (HPAPIs) up to occupational exposure bands (OEB) 4-5 in both North America and Europe.

“This is exactly the type of exciting opportunity we envisioned when we joined forces with Capsugel,” said Derek Hennecke, president, Xcelience, a division of Capsugel Dosage Form Solutions. “Over the past decade, Xcelience has developed an unrivaled proficiency in micro-dosing, producing more than 600 PIC/PIB batches. As part of Capsugel, we can now extend our expertise to a broader set of customers, while helping to bring Capsugel’s early-phase design and development offerings to a whole new level.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics